Biomedical subjects
D Mallory
Publications and source records attributed to D Mallory.
Rare blood. An ISBT Working Party report on rare blood donors. International Society of Blood Transfusion.
Explore the source record for details and available documents.
Intravenous anti-D treatment for immune thrombocytopenic purpura.
Explore the source record for details and available documents.
Use of the MAIEA assay to demonstrate that Fy3 is on the same glycoprotein as Fy6, Fya, and Fyb.
The monoclonal-antibody immobilization of erythrocyte antigens (MAIEA) assay is a technique that detects trimolecular complexes formed by a human antibody and a mouse monoclonal antibody with specific red cell epitopes. This enzyme-linked immunoadsorbent assay test gives a positive reaction when two different epitopes on the same membrane protein are separately recognized by human and mouse antibodies. In this study, the MAIEA test was used to determine if the Duffy system antigen Fy3 is on the same membrane protein as Fy6. The well-established location and relationship of Duffy blood group antigens Fya, Fyb, and Fy6 were again confirmed by the MAIEA assay, and those facts were used to standardize a variation of the assay to establish the relationship between Fy3 and Fy6 using red cells with various Fy phenotypes. The MAIEA assay generated high absorbance values when Fy6 and Fya (or Fyb) antigens were evaluated. Similarly, high absorbance values were seen when Fy3 and Fy6 antigens were tested using Fy(a+b+), Fy(a+b-), and Fy(a-b+) red cells. The MAIEA assay is a valid technique for detecting Duffy system antigens. By this technique, it was shown that Fy3 and Fy6 antigens are carried on the Duffy glycoprotein D and by extension that Fy3 is also located on the Duffy glycoprotein D.
GIL: a red cell antigen of very high frequency.
A new high-frequency red cell antigen has been identified and named GIL. GIL differs from all high-frequency antigens included in the International Society of Blood Transfusion classification. There is very little family information and GIL has not been shown to be an inherited character. Five women with anti-GIL have been found. All had been pregnant at least twice. Red blood cells of two of the babies gave positive direct antiglobulin tests, but there were no clinical signs of hemolytic disease. Anti-GIL may have been responsible for a hemolytic transfusion reaction and results of monocyte monolayer assays of two of the anti-GIL suggested a potential to cause destruction of transfused GIL+ RBCs.
Screening with monoclonal anti-Fy3 to provide blood for phenotype-matched transfusions for patients with sickle cell disease.
BACKGROUND: In the United States, there is a shortage of blood group phenotype-matched red cells (RBCs) for patients with sickle cell disease (SCD). A protocol designed to supply phenotype-matched RBCs for these patients by combining the recruitment of African American blood donors and automated testing of RBCs for these patients for the presumptive Fy(a-b-) phenotype using monoclonal anti-Fy3 was evaluated. STUDY DESIGN AND METHODS: African American donors were recruited, to increase the likelihood of phenotype matches in the donor population. Samples of RBCs were tested for the presumptive Fy(a-b-) phenotype by using monoclonal anti-Fy3 and an automated blood typing analyzer. RBCs confirmed to be Fy(a-b-) were retyped for selected Rh, MNS, Kell, Duffy, and Kidd blood system antigens. The extended phenotypes were matched with those of 41 SCD patients requiring transfusions. RESULTS: Of 8323 blood donations during the study, approximately 40 percent (3329) were made by African Americans. Approximately 22 percent (737) of African Americans were identified as Fy(a-b-) by this protocol and 12 percent (410) were phenotype matches for the 41 SCD patients. CONCLUSION: Combining the recruitment of African American blood donors and automated phenotyping using monoclonal anti-Fy3 offers a practical, relatively low-cost strategy for supplying phenotype-matched RBCs for SCD patients. This protocol increases the options for addressing the shortage of phenotype-matched RBCs for SCD patients.
Terminology for red cell surface antigens. Makuhari Report.
Explore the source record for details and available documents.
IgA anaphylactic transfusion reactions.
IgA anaphylactic transfusion reactions are rare events, estimated to occur in 1 in 20,000 to 47,000 transfusions. The signs and symptoms of these reactions do not differentiate them from other causes of anaphylaxis. The diagnosis of an anaphylactic transfusion reaction is established by showing an IgA-antibody in the patient's serum. Most laboratories that test for IgA antibodies rely on the PHA method, which uses red blood cells that are coated with serologically defined IgA multiple myeloma proteins. We tested sera referred from Red Cross regional blood centers and hospitals from patients with suspected IgA anaphylactic reactions and found an IgA antibody in 76.3% of IgA-deficient patients. However, only 17.5% of all samples referred contained an IgA antibody, indicating that most persons with suspected IgA anaphylactic reactions had experienced acute generalized reactions that were from causes other than anti-IgA transfusion. Using PHIA to measure serum concentrations of IgA and PHA to detect IgA antibodies, we found the frequency of IgA deficiency (< 0.05 mg/dL) and class-specific anti-IgA in random blood donors to be approximately 1 in 1,200. Titers of anti-IgA did not distinguish these seemingly healthy blood donors from patients with a history of an anaphylactic transfusion reaction. Because the frequency of 1 in 1,200 greatly exceeds the observed frequency of anaphylactic reactions in transfused persons, we conclude that using PHA for anti-IgA does not reliably predict risk for an anaphylactic transfusion reaction. Additional research is needed to define a more specific marker to identify those persons who are truly at risk for these serious, but rare, complications of blood transfusion.
Controversies in transfusion medicine. Prewarmed tests: pro-why, when, and how-not if.
Explore the source record for details and available documents.
Biological functions of blood groups in health and disease.
Biochemical studies reveal that erythrocyte blood group antigens are the immunological expression of polymorphic and, frequently, biologically-active membrane structures. Some of these structures have been identified to be specific transport proteins, enzymes, or receptors for infectious agents. Certain erythrocyte phenotypes, for example, Rh(null), lack all or most antigens in a specific blood group system. Changes in erythrocyte morphology and function associated with these phenotypes provide insights into the roles of the corresponding proteins in the maintenance of membrane integrity. Other phenotypes, for example Oh, and p, also lack multiple blood group antigens, but the absence of changes in morphology or function in these erythrocytes suggests that their corresponding carbohydrate determinants are not essential for maintaining membrane integrity. Additional information on the function of erythrocyte membrane structures that express blood group antigens is likely to advance our understanding of the role of blood groups in health and disease.
Hemagglutination assays for the diagnosis and prevention of IgA anaphylactic transfusion reactions.
Passive hemagglutination assays (PHA) may be used to detect IgA antibodies to confirm clinical diagnoses of suspected IgA anaphylactic transfusion reactions. Passive hemagglutination inhibition assays (PHIA) may be used to identify IgA-deficient blood donors whose plasma-containing components are transfused to prevent anaphylactic transfusion reactions in prospective recipients at risk because of the presence of IgA antibodies. Using a standard PHA, we detected class-specific anti-IgA in 76.3% of 80 IgA-deficient patients with a history of an anaphylactic transfusion reaction, and in 21.7% of 97 asymptomatic IgA-deficient blood donors or their IgA-deficient family members. Using PHIA, we confirmed IgA deficiency (< 0.05 mg/dL) for the donors of 525 plasma-containing blood components that were transfused without acute clinical reactions to 48 IgA-deficient recipients with anti-IgA and/or a history of an anaphylactic transfusion reaction. The frequency of IgA-deficiency with class-specific anti-IgA among 32,376 random blood donors was 0.08% (1/1,200). The combined use of PHA for detecting anti-IgA and PHIA for measuring IgA concentration provides an effective and safe strategy for the diagnosis and prevention of IgA anaphylactic transfusion reactions. However, PHA for anti-IgA lacks specificity for identifying persons who are truly at risk for significant anaphylactic transfusion reactions. The consequence is an overdiagnosis of IgA anaphylactic transfusion reactions and an overestimation of the number of persons at risk for IgA anaphylactic transfusion reactions because of the detection of an IgA antibody in their serum.
Cefotetan-induced immune hemolytic anemia due to the drug-adsorption mechanism.
Positive direct antiglobulin tests (DATs) associated with cephalosporin therapy have been reported, but rarely were associated with immune hemolytic anemia (IHA). In 1989, we described the first case of IHA associated with cefotetan (Cefotantrade mark) causing hemolysis by the drug-adsorption mechanism. We now report the full details of ow investigation. The patient was a 23-year-old female with a 2 1/2 year history of chronic ulcerative colitis. After 4 days of therapy with cefotetan (2 g/day), her hematocrit (Hct) decreased from 34.351 to 23.3%. The reticulocyte count was 6.9%. The DAT was 2+ (IgG only), and the serum and an eluate were nonreactive with a panel of standard reagent red blood cells (RBCs). Cefotetan therapy continued and the patient was transfused with two units of RBCs. On day 6 of therapy, the patient experienced an anaphylactoid reaction attributed to sensitivity to cefotetan. Cefotetan therapy was discontinued, the patient was treated with corticosteroids and epinephrine, and she was transfused with an additional unit of RBCs. Her Hct rose to 34.1% prior to her discharge on day 11. Further investigation revealed that the patient's serum and an eluate contained an antibody that reacted with cefotetan- and cephalothin-coated RBCs by the indirect antiglobulin test. In a monocyte monolayer assay, monocytes readily phagocytized cefotetan- and cephalothin-coated reagent RBCs but not uncoated reagent RBCs. The patient's serum did not react by the so-called immune-complex mechanism when cefotetan or cephalothin was added to the patient's serum + complement + RBCs.
Misidentification of anti-Vel due to inappropriate use of prewarming and adsorption techniques.
Two units of red blood cells (RBCs) were ordered for a 44-year-old Caucasian woman with renal failure and cancer. Pretransfnsion testing performed at the regional reference laboratory had revealed the presence of an antibody reactive with all cells at the indirect antiglobulin test but apparently nonreactive by a prewarmed IAT. The patient's RBCs were direct antiglobulin test negative. Adsorption of the serum with rabbit erythrocyte stroma or with allogeneic RBCs at 4 degrees C reduced the reactivity at the IAT. The patient was transfused with two units of washed RBCs and died 6 to 8 hours later. Retrospective testing in our laboratory detected anti-Vel in both pretransfusion and posttransfusion samples. The pretransfnsion serum was hemolytic when tested io LISS or with papain-treated RBCs. Weak reactivity (I+) was observed at the IAT. EDTA-treated serum (to prevent C'-mediated hemolysis) was strongly reactive (3+s) with Vel+ RBCs but compatible with 10 examples of Vel- RBCs. Adsorptions with rabbit RBCs did not affect reactivity. Pretransfnsion RBCs were nonreactive with three examples of anti- Vel at the IAT. The posttranshision serum was grossly hemolyzed and anti-Vel was demonstrable, although weaker than in the pre- transfusion sample. The antibody was subclassed as IgG1 and IgG3. In this case, the use of a prewarming technique precluded detection of hemolysis caused by the antibody prior to the IAT. This case stresses the importance of antibody identification and the correct use of such techniques as prewarming and adsorptions.
A comparison of the monocyte monolayer assay with 51chromium red cell recovery for determining the clinical significance of red cell alloantibodies.
Explore the source record for details and available documents.
First example of Rh:-32,-46 red cell phenotype.
The red cells of a white male blood donor typed as Rh:-1, -2, -3,w4,w5,6,-17,w19,-31,-32,-34, and -46. Although the donor has no history of transfusion, his serum contains an alloantibody that is weakly reactive with most red blood cells (RBCs) tested. Only Rhnull and D-- RBCs are nonreactive. Reactivity is enhanced with ficin- or papain-treated RBCs and is unaffected by AET or DTT treatment of the RBCs. Previously described Rh:-46 RBCs have been of deletion types D--, D, and Rhnull, or Rh:32. In three multitransfused patients, the Rh46 antigen was temporarily suppressed and the phenotype eventually reverted to normal. This is the first report of RBCs of the Rh:-32,-46 phenotype that are not of a rare Rh deletion or Rhnull type. In addition, the Rh:w5,w19,-31,-34 phenotype is rarely found in whites.
A decade of rare donor services in the United States. Report of the American Red Cross Rare Donor Registry (1981-1990).
Between 1981 and 1990, the American Red Cross Rare Donor Registry supplied 9,872 units of red cell components with rare phenotypes to blood centers in the United States and abroad. Approximately 51% were from donors with high-frequency antigen-negative phenotypes and 49% were from donors with multiple antigen-negative phenotypes. Since 1989, the disease category requiring the largest number of units has been sickle cell disease. Strategies to ensure that the Registry will have adequate resources to meet future requirements include testing selected donors for rare phenotypes and blood conservation programs, such as intraoperative salvage and the treatment of anemia of chronic renal failure with recombinant erythropoietin.
International experts met at the United States Food and Drug Administration.
Explore the source record for details and available documents.